Can inhibition of glutamate transport contribute to the actions of neuroleptics?

Psychiatrie

Volumn 7, Issue 1, 2003, Pages 6-11

  Stanton, David ^a   Liao, Lee P ^a   Moussa, Charbel El Hajj ^a   Bubb, William A ^a   Rae, Caroline ^a   Balcar, Vladimir J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chlorpromazine; Clozapine; Glutamate transport inhibitors; Glutamatergic neurotransmission; Haloperidol; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT;

AMINO ACID TRANSPORT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; STRUCTURE ANALYSIS;

EID: 0037255437     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Balcar VJ, Johnston GAR. The structural specificity of the high affinity uptake of L-glutamate and L-aspartate by rat brain slices. J Neurochem 1972;19:2657-2666.
2. Balcar VJ, Johnston GAR, Twitchin B. J Neurochem 1977;28:1145-1146.
3. Balcar VJ, Li Y. Heterogeneity of high affinity uptake of L-glutamate and L-aspartate in the mammalian central nervous system, Life Sci 1992;51:1467-1478.
4. Balcar VJ, Takamoto A, Yoneda Y. Neurochemistry of L-glutamate transport in the CNS: a review of thirty years of progress. Collect Czech Chem Commun 2001;66;1315-1340.
5. +-dependent transport of amino acids in the mammalian CNS. Biol Pharm Bull Pharm Soc Japan 2002;25:291-301.
6. Bennett MR, Balcar VJ. Forty years of amino acid transmission in the brain. Neurochem Internat 1999;35:269-280.
7. 14C)glutamic acid under basal conditions and in hypoglycemic coma. Acta Nerv Super (Praha) 1972;14:40-45.
8. Blakely RD. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 2001:21:8319-8323.
9. Bridges RJ, Kavanaugh MP, Chamberlin AR. A pharmacological review of competitive inhibitors and substrates of high affinity, sodium-dependent glutamate transport in the central nervous system. Curr Pharm Des 1999;5:363-379.
10. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001;41:237-260.
11. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;65:1-105.
12. De Souza IE, McBean GJ, Meredith GE. Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur J Pharmacol 1999;382:139-142.
13. Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer disease. Prog Brain Res 1998;116:421-437.
14. Ishimaru MJ, Toru M. The glutamate hypothesis of schizophrenia: therapeutic implications. CNS Drugs 1997;7:47-67.
15. Johnston GAR, Kennedy SMF, Twitchin B. Action of the neurotoxin kainic acid on high affinity uptake of L-glutamic acid by brain slices. J Neurochem 1979;32:121-127.
16. Melone M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, Pérez-Samartin A, Mature C, Cozzi A, Pelleqrini-Giampietro DE, Rothstein JD, Conti F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 2001;6:380-386.
17. Moussa CE-H, Mitrovic AD, Vandenberg RJ, Provis T, Rae C, Bubb AW, Balcar VJ. Effects of L-glutamate transport inhibition by a conformationally restricted glutamate analogue (2S,1'S,2'R)-2- (carboxycyclopropyl)glycine (L-CCG III) on metabolism in brain tissue in vitro analysed by NMR spectroscopy. Neurochem Res 2002;27:27-35.
18. Nakamura Y, Kataoka K, Ishida M, Shinozaki H. (2S,3S,4R)-2- (Carboxycyclopropyl) glycine, a potent and competitive inhibitor of both glial and neuronal uptake of glutamate. Neuropharmacology 1993;32:833-837.
19. Rae C, Lawrance ML, Dias LS, Provis T, Bubb WA, Balcar VJ. Strategies for studies of neurotoxic mechanisms involving deficient transport of L-glutamate: antisense knockout in rat brain in vivo and changes in the neurotransmitter metabolism following inhibition of glutamate transport in guinea pig brain slices. Brain Res Bull 2000;53:373-381.
20. Sawa A, Snyder SH. Schizophrenia: Diverse approaches to a complex disease. Science 296:692-695.
21. Schneider JS, Wade T, Lidsky TI. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. Neuroreport 1998;9:133-136.
22. Shimamoto K, Lebrun B, Yasuda-Kamatani Y, Sakaitami M, Shigeri Y, Yumoto N, Nakajiam T. DL-Threo-?-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol 1998;53;195-201.
23. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of excitatory amino acids transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 2001;158;1393-1399.
24. Ŝt'astný F, Pliss L, Bubeníková V. Uνloha N-acetyl-aspartyl-glutamátu v modelu schizofrenie (Role of N-acetyl-aspartyl-glutamate in schizophrenia model) Psychiatrie 2001;5(S3):10-14.
25. Tsuneizumi T, Babb SM, Cohen BM. Drug distribution between blood and brain as determinant of antipsychotic drug effects. Biol Psychiatry 1992;32:817-824.
26. Vandenberg RJ, Mitrovic AD, Chebib M, Balcar VJ, Johnston GAR. Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol 1997;51:809-815.